Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan current therapeutic effects and perspectives for clinical use
- 1 April 1990
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 81 (3) , 233-243
- https://doi.org/10.1016/0021-9150(90)90071-p
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKEThe Lancet, 1987
- The Effectiveness of Glycosaminoglycans in Peripheral Vascular Disease Therapy: A Clinical and Experimental TrialJournal of International Medical Research, 1985
- Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxisJournal of Molecular Medicine, 1984
- Partial structure of the active moiety of a lipoprotein complexing proteoglycan from human aortaAtherosclerosis, 1983
- Structure and Metabolism of Proteoglycans and Glycosaminoglycans.Journal of Investigative Dermatology, 1982
- Glycosaminoglycans and Their Binding to Biological MacromoleculesAnnual Review of Biochemistry, 1978
- PROPHYLAXIS AGAINST POSTOPERATIVE PULMONARY EMBOLISM AND DEEP-VEIN THROMBOSIS BY LOW-DOSE HEPARINThe Lancet, 1978
- Effect of some mucopolysaccharides on activated factor XBiochemical Pharmacology, 1978
- Plasma glycosaminoglycans in normal individuals of various ageAtherosclerosis, 1977
- A HEPARIN ANALOGUE WITH SPECIFIC ACTION ON ANTITHROMBIN IIIThe Lancet, 1977